Peter A. Thompson - 25 Jun 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Director
Issuer ticker: SPRY
Reported as of: 25 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2025, 16:30:15 UTC
Prior SEC filing: 18 Jun 2025
Next SEC filing: 01 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Kathleen Scott, Attorney-in-Fact

Key filing fact

Peter A. Thompson filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 27 Jun 2025.

Key facts

This page summarizes Peter A. Thompson's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jun 2025, 16:30.

Change

Previous filing in this sequence was filed on 18 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001357522 Primary reporting owner

Thompson Peter A.

Relationship: Director
Address: C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Signature: /s/ Kathleen Scott, Attorney-in-Fact
Signature date: 27 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 25 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $17.26
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.